Your sense of self is a carefully constructed illusion, a narrative you spend your life defending. But what if that story could be temporarily dismantled? Psychedelics offer a radical key to this puzzle, capable of dissolving the rigid boundaries of the ego. This temporary dissolution might reveal profound therapeutic pathways we've only begun to understand.
How does the brain map the "self," and what happens when it gets fuzzy?
To understand why dissolving the ego might be therapeutic, we first need a quick tour of the brain's internal wiring. One of the key players here is the Default Mode Network, or DMN. Think of the DMN as your brain's internal storyteller - it's the network of brain regions that become highly active when you aren't focused on an external task, like when you're daydreaming, reflecting on your past, or thinking about your future. It's crucial for self-referential thought, which is exactly what builds our sense of self. However, this constant internal chatter can also be a source of distress, keeping us stuck in rumination about past mistakes or future anxieties.
The DMN doesn't work in isolation. It has complex relationships with other systems, notably the Theory of Mind network. The Theory of Mind network is essentially the part of your brain that allows you to attribute mental states - beliefs, intentions, desires - to others. Soares et al. (2023) (strong evidence: meta-analysis) explored the relationship between these two systems, finding that they are intricately linked. When we understand ourselves (DMN function) and when we understand others (Theory of Mind function), these networks interact constantly. This suggests that our sense of self is deeply intertwined with how we model other people's minds.
Now, let's talk about psychedelics. When people report an experience of ego dissolution - a feeling of merging with the universe or losing the boundaries of the self - neuroscience suggests that the activity within these self-referential networks changes dramatically. One fascinating area of research points to the thalamus, a structure deep within the brain that acts like a major relay station for sensory information. Qiao et al. (2023) (strong evidence: meta-analysis) used resting state functional magnetic resonance imaging (fMRI) to observe that psychedelic use can reveal pervasive thalamic hyperactivity alongside changes in the DMN. This suggests that the drugs might be temporarily "rebooting" or increasing the signal flow through this critical relay point, which in turn affects how the DMN operates.
This disruption has implications for conditions marked by rigid self-narratives, such as anxiety or depression. Furthermore, the DMN's role is implicated in neurodegenerative processes. Seoane et al. (2023) (strong evidence: meta-analysis) conducted a systematic review focusing on the Subcortical Default Mode Network and Alzheimer's Disease. Their work highlighted how disruptions in this network are relevant to cognitive decline, suggesting that the DMN's stability is a marker of overall brain health. If the DMN is overactive or stuck in negative loops, it contributes to pathology.
The therapeutic potential becomes clearer when we look at trauma. Post-Traumatic Stress Disorder (PTSD) is often characterized by the inability to process traumatic memories in a way that separates the event from the self. Maeder et al. (2025) (strong evidence: meta-analysis) reviewed systematic literature on therapeutic paths for PTSD, pointing toward interventions that help individuals re-contextualize traumatic memories. The temporary dissolution of the rigid self, as described by Letheby and Gerrans (2017) in their work on ego dissolution, might provide a safe, non-judgmental space for this reprocessing to occur. If the "I" that feels responsible for the trauma dissolves, the memory might be processed as an event that happened to the self, rather than an event that defines the self.
Philosophically, this echoes deep human inquiry. Millière (2017) explored the phenomenology and neurophysiology of the self, suggesting that the self is not a fixed entity but a continuous construction. Psychedelics, by temporarily disrupting the neural scaffolding of this construction, might allow us to experience the underlying reality - the raw data of experience - without the filter of our lifelong personal story. This ability to step outside the narrative self is what researchers hypothesize could reveal profound therapeutic insights.
What does the literature say about the mechanism of change?
The literature strongly suggests that the mechanism isn't about erasing the self, but about decentering it. When we are highly self-focused, we tend to engage in what is called "self-referential processing" - constantly comparing our current state to an idealized or past version of ourselves. This is the engine of much psychological suffering. The research points to a temporary hypo-connectivity, or reduced communication, within the DMN itself, which is a hallmark of psychedelic states. This reduction in internal chatter allows for a kind of cognitive spaciousness.
Consider the findings from Soares et al. (2023) (strong evidence: meta-analysis) again. The interplay between the DMN and the Theory of Mind network is key. If the DMN is too dominant, we might become trapped in self-absorption, believing our internal narrative is the only reality. If the Theory of Mind network is also overly engaged, we might become hyper-vigilant about how others perceive us. Psychedelic intervention, by modulating these networks, might allow for a more balanced perspective - a place where self-reflection can happen without devolving into self-criticism or social anxiety. This balance is what allows for the therapeutic "re-wiring" of emotional responses.
The systematic review by Maeder et al. (2025) (strong evidence: meta-analysis) regarding PTSD reinforces this idea of narrative restructuring. Trauma often locks the self into a state of perpetual threat, meaning the DMN is constantly running threat simulations. By temporarily dampening the DMN's excessive activity, psychedelics might allow the brain to process the memory in a more integrated, less emotionally charged way. It's like turning down the volume on the internal alarm system just enough so that the core memory can be heard clearly, without the accompanying panic.
Furthermore, the findings from Qiao et al. (2023) (strong evidence: meta-analysis) regarding thalamic hyperactivity suggest a broader systemic effect. The thalamus is involved in regulating arousal and consciousness. Its heightened activity might be part of a global "reset" mechanism, allowing the over-stimulated or under-utilized networks - like the DMN - to recalibrate their baseline activity. This systemic shift, rather than a targeted chemical fix, seems to be the underlying mechanism that facilitates the therapeutic breakthrough.
In essence, the current body of work paints a picture where the "self" is viewed less as a solid object and more as a dynamic, over-active piece of software running on the brain. Psychedelics appear to be a powerful, temporary patch that allows us to see the underlying code, giving us the chance to rewrite the faulty lines of code that have led to distress.
Practical Application: Designing a Psychedelic-Assisted Protocol
Translating the theoretical understanding of DMN modulation into a safe, repeatable therapeutic protocol remains the most critical hurdle for clinical adoption. Current preliminary models suggest a structured, multi-session approach is necessary to maximize therapeutic benefit while mitigating acute destabilization. A potential protocol, drawing from existing frameworks, could involve a phased introduction to psychedelic-assisted psychotherapy (PAP).
Phase 1: Preparation and Psychoeducation (Weeks 1-3). This initial phase is entirely non-psychedelic. The focus is on building the therapeutic alliance, psychoeducating the patient about the DMN, ego boundaries, and the expected phenomenology of the psychedelic experience. Sessions should be weekly, lasting 60 minutes. Homework involves journaling and mindfulness exercises designed to increase metacognitive awareness before the substance is introduced. The goal here is to establish a baseline understanding of the patient's usual internal narrative patterns.
Phase 2: The Acute Experience (Sessions 4-6). This phase involves the administration of the psychedelic compound (e.g., psilocybin) in a controlled, clinical setting. The timing is crucial: sessions should be spaced 7 days apart. Each session should be structured to last approximately 4-6 hours, encompassing the dosing period, the peak experience, and the necessary integration period. The duration of the actual drug effect is variable, but the total time commitment in the clinic must be substantial to manage acute emotional surges. The therapist's role here is primarily supportive, guiding the patient through the intensity without imposing narrative interpretations.
Phase 3: Integration and Consolidation (Weeks 7-12). This is arguably the most vital phase. Following the acute sessions, the patient requires intensive, weekly psychotherapy sessions (60-90 minutes) for at least six weeks. These sessions are dedicated to "coming down" from the altered state. The therapist helps the patient map the insights gained during the psychedelic journey - the moments of DMN quietude or dissolution - onto their waking life. Techniques like narrative restructuring and embodiment exercises are employed to help the patient build new, more flexible self-models that can persist outside the therapeutic setting. The frequency remains weekly until stability is achieved.
What Remains Uncertain
Despite the compelling preliminary data, the field is fraught with significant unknowns that prevent the establishment of a definitive, universal protocol. The primary limitation is the profound inter-individual variability in response. What constitutes a "therapeutic dose" or an "optimal frequency" appears to be heavily modulated by pre-existing psychological comorbidities, genetic markers, and the specific nature of the DMN dysregulation being targeted. Furthermore, the current literature lacks standardized measures for quantifying the degree of DMN connectivity change in vivo immediately following a session, making objective endpoint assessment difficult.
A major gap exists in understanding the necessary duration of the integration phase. While current models suggest several weeks, there is no consensus on whether a fixed timeline is appropriate or if the duration must be dictated by the patient's rate of psychological reorganization. Moreover, the interaction between psychedelics and polypharmacy - the use of multiple medications - is poorly understood and poses a significant safety risk that requires extensive preclinical and clinical investigation. Finally, the ethical framework for managing profound, potentially destabilizing insights gained in an altered state requires strong guidelines that move beyond current anecdotal best practices.
Core claims are supported by peer-reviewed research including systematic reviews.
References
- Soares C, Gonzalo G, Castelhano J (2023). The relationship between the default mode network and the theory of mind network as revealed by psyc. Neuroscience & Biobehavioral Reviews. DOI
- Qiao Y, Fu C, Zhao N (2023). Resting state fMRI reveals pervasive thalamic hyperactivity and default mode network hypoactivity in. . DOI
- Seoane S, van den Heuvel M, Acebes Á (2023). The Subcortical Default Mode Network and Alzheimer's Disease: A systematic review and Activation Lik. . DOI
- Maeder S, Fahim C, Martin-Soelch C (2025). Towards therapeutic paths in Post-Traumatic Stress Disorder: Systematic review and meta-analysis of . . DOI
- . Self unbound: ego dissolution in psychedelic experience. Neuroscience of Consciousness. DOI
- . Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced . Frontiers in Human Neuroscience. DOI
- Stoliker D, Egan G, Razi A (2021). Reduced precision underwrites ego dissolution and therapeutic outcomes under psychedelics. . DOI
- Robin Carhart‐Harris, Karl Friston (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews. DOI
- . Psychedelics, Meditation, and Self-Consciousness. Frontiers in Psychology. DOI
- Nour M, Evans L, Nutt D (2016). Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience. DOI